A HYBRID CHAOTIC-BASED MULTIOBJECTIVE DIFFERENTIAL EVOLUTION TECHNIQUE FOR ECONOMIC EMISSION DISPATCH PROBLEM



HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

Abstract DESTINY-CRC01 (NCT03384940) was a Chewing Gum multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic colorectal cancer (CRC).The present exploratory biomarker analysis aims to investigate relati

read more